Trial Profile
An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia; Gastrointestinal stromal tumours; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 07 Aug 2023 Status changed from active, no longer recruiting to completed.
- 05 Jul 2023 Planned End Date changed from 28 Jun 2023 to 7 Jul 2023.
- 05 Jul 2023 Planned primary completion date changed from 28 Jun 2023 to 7 Jul 2023.